Melanoma is an increasingly important public health problem. Although the cause of most malignant melanomas – over-exposure to ultraviolet light – is well known, effective treatment has remained challenging. The past several years have been marked by extraordinary developments in melanoma treatment in the arena of targeted therapeutics. This book describes these ground-breaking discoveries and their implications for clinical use. As melanoma biology is increasingly understood, so the development of targeted therapies for this disease is spurred ahead. This book covers both established signal transduction inhibitors and the fascinating emerging realm of molecularly-guided immunotherapies. Thisbenchmark book provides the most up-to-date information on the new breed of melanoma therapies. Composed of the works of major researchers and clinicians, this book offers new insights, novel approaches, and promising data for effective treatment planning. Illuminating the latest advances in the field, it is asolid resource for clinical oncologists, translational scientists, and basic cancer researchers. Describes both established signal transduction inhibitors as well as emerging molecularly-guided immunotherapies. Places exciting developments in basic biological understanding into a practical clinical context. The first book on melanoma devoted entirely to targeted therapeutics. Includes the most up-to-date data from current clinical Phase I-III trials. Written by high-profile authors representing the world’s leaders in their field. INDICE: Molecular targets and subtypes in melanoma. Melanoma genomics. Predictive biomarkers as a guide to future therapy selection in melanoma. KIT as a therapeutic target for melanoma. Targeted inhibition of B-Raf. The notch andB-catenin pathways. STAT3 and Src signaling in melanoma. Targeting the mTOR, PI3K and AKT pathways in melanoma. Targeting apoptotic pathways in melanoma. Anti-angiogenesis therapy in melanoma. Melanoma antigens recognized by T lymphocytes. Melanoma vaccines. Adoptive cell therapy for the treatment of metastatic melanoma. Anti-CTLA-4 monolonal antibodies. Anti-PD-1 and Anti-B7-H1/PD-L1 monoclonal antibodies. Treatment of melanoma with agonist immune co-stimulatoryagents. Novel cytokines for immunotherapy of melanoma. Modulating the tumor microenvironment.
- ISBN: 978-1-61779-406-3
- Editorial: Humana Press
- Encuadernacion: Cartoné
- Páginas: 452
- Fecha Publicación: 28/01/2012
- Nº Volúmenes: 1
- Idioma: Inglés